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It was stated years ago that physicians pour
medicines about which they know little, for diseases
about which they know less, into human beings about
whom they know nothing.' Although as a prophet
this wag may have overstated the case as it concerns
the therapy of urinary tract infections (UTI), the
character of contemporary infectious diseases is, in
part, due to the use and abuse of anti-infective
agents. 2 •3 One has only to look at the rising incidence
of gram-negative bacteremia and the emergence of
multiple antibiotic-resistant organisms over the past
several decades to appreciate the impact physicians
have made with these agents.4· 5 Despite the drawbacks, the benefits resulting from the use of antibiotics far outweigh the deleterious effects, a fact perhaps
realized most vividly by physicians whose careers
reach back to the pre-chemotherapeutic era. The enthusiasm for antibiotics makes them one of the most
prescribed groups of drugs in the United States, accounting for 15% to 20% of all new and refill prescriptions.6 Undoubtedly many of the prescriptions
are used to treat persons with UTis, in light of the
fact that UTls are said to rank second only to upper
respiratory infections as the most common infections
in the western hemisphere.7

Principles of Therapy
Without belaboring the point, how does the physician steer his way through the many antibiotics
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which are promoted so vigorously by pharmaceutical
companies, perhaps in response to the competitive
pressures and potential profits of what has become a
multi-billion dollar industry? Certain characteristics
are desirable in any antibiotic, and it behooves the
physician to consider these characteristics when evaluating the potential usefulness of the agent. 8
I. Activity. An agent with bactericidal activity
against a wide spectrum of microorganisms, and one
that doesn't disturb normal flora or lead to the emergence of resistant organisms should be sought.
2. Toxicity. Adverse reactions should be infrequent, and teratogenicity absent.
3. Pharmacology. Pharmacologic properties should
be such that adequate concentrations of the drug are
achieved and maintained near the organism for prolonged periods.
4. Physicochemica/ properties. The drug should
be stable ( dry or in solution) tolerant of pH changes,
and readily absorbable from the gastrointestinal (GI)
tract.
5. Interactions . The drug should not interact with
other therapeutic agents.
6. Cost. The agent should be inexpensive and
hence available to all who need it.
Of course, no such "magic bullet" exists, and
because it doesn't, one should be guided , when treating UTis, by certain fundamental principles.9
I. The presence of a bacterial infection shou ld be
established. Symptoms alone are not sufficient evidence for the diagnosis of UTI, as up to 50% of
women with dysuri a and frequency have sterile
urine.10 The finding of one or more bacteria per oil
field in a Gram stain of uncentrifuged urine correlates
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well ( over 90%) with the presence of 100,000 organisms or more per ml of urine. Numbers of this
magnitude usually indicate true infection (significant
bacteriuria) and not procurement contamination
with gram-negative enteric bacilli. In an asymptomatic person, three consecutive daily urine cultures
obtained by the clean-voided method and each containing 100,000 organisms per ml of the same bacterium indicate that the patient has at least a 95%
chance of having a UTI. 11 In a symptomatic person,
bacteria seen on microscopic examination and one
urine culture containing 100,000 organisms or more
per ml carries the same 95% probability of true infection.
2. The elimination of bacteriuria requires the use
of antibiotics which are active against the common
urinary pathogens and which achieve inhibitory concentrations in the urine, not the serum. Disappearance of bacteriuria correlates well with the
sensitivity of the organism to achievable urinary levels.12·18 This serves to underline the obvious discrepancies sometimes seen between antibiotic sensitivities in vitro and the eradication of bacteriuria.
3. Underlying urinary tract abnormalities, particularly obstructive or neurogenic lesions, should be
corrected if possible; obstruction from whatever
cause not only has a compromising effect on renal
function but it also practically eliminates the likelihood of successful antibiotic therapy.
4. The hallmark for the eradication of infection
is the absence of bacteriuria following the cessation
of therapy. Symptomatic improvement is a poor indicator of successful therapy because symptoms may
improve with only the slightest suppression of bacteriuria. In addition, while bacteriuria may disappear
during therapy, recurrence of the original organism
(see below) is common and can be detected only by
obtaining cultures after the completion of therapy.
5. Prolonged follow-up is required to insure permanent cure of the UT!. Recurrence of an initially
symptomatic and apparently successfully treated infection may be asymptomatic, and constant vigilance
by the physician can pay dividends in reduced morbidity from UT!s. This is done usually by obtaining
periodic urine cultures (Figure). A culture obtained
between 48 to 72 hours after the initiation of therapy
should be sterile. If it is not, then the therapy should
be recognized as a failure and the patient should be
treated with an appropriate antibiotic chosen on the
basis of sensitivity tests. If the culture is negative,
additional cultures should be obtained one to two

weeks following completion of therapy, monthly for
three months, then at three-month intervals for one
to I V2 years. The patient should be considered cured
if there is no recurrence during the period of observation.
Therapeutic Agents
The goal of therapy for UT!s is the elimination
of bacteriuria and the most effective way of achieving
this is with antibiotic therapy. The antimicrobial
agents frequently used to treat UT!s are listed in the
Table. Most share the common characteristics of
being active against the majority of common urinary
tract pathogens and being excreted at high concentrations into the urine.
Sulfonamides. The sulfonamides were the first
group of agents shown to be consistently useful for
treating UT!s. Many effective sulfonamides are available, but the short-acting, oral nonabsorbable drugs,
such as sulfisoxazole and sulfamethoxazole, are generally recommended. These agents achieve high urinary concentrations and are soluble at an acid pH.
Toxicity is relatively infrequent. They are especially
effective against Escherichia coli and Proteus mirabilis
but generally are useful only for the first few episodes
of infection because of the emergence of resistant
bacteria. Although sulfonamides offer no real advantage over other agents, they are inexpensive (see
Table) and hence available to most patients. Sulfonamides should not be used in persons with glucose-6phosphate dehydrogenase deficiency, in pregnant
women near term, and in newborn infants because of
the danger of producing kernicterus in the neonate.
Penicillins. Among the penicillins, ampicillin remains the drug of choice for UT!s. It is effective
against many gram-positive and gram-negative organisms and reaches adequate levels in the renal medulla. Ampicillin is the preferred agent for pregnant
women and newborns, and is especially useful in
treating UT!s due to susceptible organisms in patients .with renal insufficiency. There is no evidence to
indicate that ampicillin is superior to sulfonamides in
the management of uncomplicated UT!s (see below),
just as there is no evidence to indicate that newer
penicillin derivatives, such as amoxicillin, are superior to ampicillin. Diarrhea is frequent and rashes
occur in 5% to 10% of patients. 1
Tetracyclines. The tetracyclines have been relegated to a less prominent role in the treatment of
UT!s. The best urinary levels are achieved with tetracycline and oxytetracycline. 11 Newer derivatives,
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bacteriuria*

Acute
Symptoms*

!

!

culture urine and
begin therapy

2 consecutive cultures
with same organism
precedes therapy

Culture urine

+

If bacteriological and/or
clinical response, treat
for 10-14 days

Reinfection

l

Retreat with appropriate
drug 10-14 days

Relapse

~

Consider therapy
for 6 weeks

Negative
cultures

l

CURE

CURE

Reinfection

If frequent,
consider long
term prophylaxist

If occassional treat
each episode for
10-14 days

Relapse

l

Consider therapy
for 6-12 months

CURE

* Radiographic evaluation should be obtained on all children,
all men, young women, and probably in all patients with
bacteremia
t Not in asymptomatic elderly without obstruction
Figure-Diagrammatic approach to the management of urinary tract infections.
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TABLE
Antibiotics Useful in the Therapy of Urinary Tract Infections in Adults
Antibiotic

Oral:
Sulfisoxazole
Sulfamethoxazole
Penicillin G
Ampicillin
Amoxicillin
Tetracycline
Cephradine
Cephalexin
Nitrofurantoin
Nalidixic acid
Trimethoprim-Sulfamethoxazole
Parenteral:
Ampicillin
Carbenicillin
Cephalothin
Cefazolin
Gentamicin
Amikacin

Tradename(s)

Dosage•

Co st in dollars (dose)b

Gantrisin
G a ntanol
Many
Many
Larotid , Amoxil
Many
Velosef, Anspor
Ke flex
Furadantin
Macroda ntin
NegGram
Bactrim , Septra

0 .5-1.0 gm q 4-6 h
I.Ogm q 8-12 h
0.4-0.8 X I0'µ q 6 h
0.5-1.0 gm q 6 h
0.25-0.5 gm q 8 h
0.25-0.5 gm q 6 h
0.5gm q 6 h
0.5gm q 6 h
0.05-0. 1 gm q 6 h
0.05-0.1 gm q 6 h
0 :5-1.0 gm q 6 h
2 tablets q 12 h

.04 (0 .5 gm)
.08 (0.5 gm)
.01 (0.2 X IO'µ)
.09 (0.5 gm)
.30(0.5gm)
.03 (0.5 gm)
.56 (0.5 gm)
.52 (0.5 gm)
.01 (0.05 gm)
.15(0.05gm)
.12 (0.5 gm)
.21 (per ta blet)

Many
Geopen , Pyopen
Keflin
Ancef, Kefzol
Garamycin
Ami kin

0.5-2 gm q 4-6 h
1-5 gm q 4-6 h
0.5-2 gm q 4-6 h
0.5-1.5 gm q 6-8 h
1-1.7 mg/ kg q 8 h
5 mg/ kg q 8 h

1.11 (I gm)
2.20(1 gm)
2.75 (I gm)
5.05 (I gm)
5.05 (per 80 mg vial)
4 .93 (per 100 mg)

• Usual average or range of dosages in patients with norm al renal function.
b Cost to pharmacist based on listings in the American Druggist Blue Book (Hearst Corp. Publishers), October 1977.

such as doxycycline and minocycline, although approved for use in UTis, have significant extrarenal
routes of excretion, so that the low urinary concentration achieved makes them Jess desirable for therapy.14 Generic tetracycline is inexpensive (see Table).
Resistance to tetracycline emerges rapidly during
therapy; however, tetracyclines are probably as effective as the· sulfonamides and ampicillin for treating
uncomplicated UTis (see below). Fulminant hepatitis
has been induced in those receiving large parenteral
doses of tetracycline (greater than 2 gm per day), and
irreversible discoloration and maldevelopment of
permanent teeth is a danger in children under age 8
who receive these drugs 14; however, GI signs and
symptoms are the most common side effects of therapy .u
Cephalosporins. The instances where cephalosporin antibiotics should be used are difficult to
define, but they are indicated possibly for treating
gram-positive coccal infections (except those caused
by enterococci and methicillin-resistant staphylococci) in patients a llergic to penicillin. These agents
are useful in treating infections due to Klebsiella
pneumoniae and antibiotic strains of E coli, P mirabilis, and other gram-negative bacilli . The use of
cephalosporin a ntibiotics for central nervous system

infections is contraindicated. 15 Although most of
these drugs achieve good urinary levels, and are
therefore effective agents for the therapy of UTis,
most are expensive (see Table) and should not be
used when cheaper, equally effective drugs are available. The two most important oral agents, cephalexin
and cephradine, are similar and can be used interchangeably.16 Up to 5% of patients develop allergic
reactions such as rash , fever, and, rarely, anaphyJaxis11; 5% to 15% of penicillin-allergic patients will
manifest allergy to the cephalosporins. 18
Aminoglycosides. The aminoglycoside antibiotics
are parenterally administered agents useful against a
wide variety of gram-negative organisms. These
drugs have the potential for ca using significant otoand nephrotoxicity 1• and should therefore be reserved
for therapy of hospitalized patients with moderate to
severe UTis caused by organisms resistant to Jess
toxic agents. Dosage should be adjusted for those
with renal insufficiency; such a lterations in dosage
can be achieved by any of several published programs.20 - 22 Gentamicin and a mikacin are two commonly used aminoglycoside antibiotics which differ
little in the incidence of toxicity.23 However, amikacin
is resistant to many more of the aminoglycosideinactivating enzymes than genta micin, 24 therefore its
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greatest utility at present is in the therapy of UTis
caused by gentamicin-resistant organisms.
Nitrofurantoin. This drug is available in crystalline and macrocrystalline forms. The latter compound is absorbed from the GI tract and excreted
more slowly than the crystalline form and allegedly
causes less GI upset. Nitrofurantoin achieves high
urine concentrations and is more active at an acid
pH . It is effective against gram-positive and gramnegative organisms except Pseudomonas sp, some Enterobacter sp, Serratia marcescens, and indole-positive Proteus. The drug may be useful for lower and
upper UTI. 11 Nitrofurantoin is contraindicated for
use in patients with renal failure because little of the
drug is found in the urine and because the incidence
of irreversible peripheral neuropathy is increased under these circumstances. 11 Small amounts of this
orally administered drug is found in the feces, which
probably accounts for the relatively low incidence of
resistant enteric organisms emerging during and after
therapy. Thus, nitrofurantoin would appear to be a
useful therapeutic and prophylactic agent for patients
with recurrent UT1s 25 (see below).
Nalidixic acid. N alidixic acid and its co gen er,
oxolinic acid, are oral antimicrobials which have virtually the same antibacterial spectrum, including
most gram-negative urinary tract pathogens except
for Pseudomonas sp, Serratia marcescens and indolepositive Proteus. Resistance develops rapidly and recurrence of infection with resistant organisms is not
uncommon. Blood and, presumably, tissue levels
are low. These agents are moderately expensive (see
Table) and should be used as alternative therapy to
other oral agents such as the sulfonamides and ampicillin.
Methenamine salts. Methenamine salts have a
limited role in the therapy of UTis. These agents are
effective against most gram-negative organisms in
vitro, but require an acid medium (pH of 6 or less)
for release from methenamine of the bactericidal
agent formaldehyde; tissue levels are low to absent.
The main uses are for suppression of bacteriuria or
prophylaxis between episodes of infection. The efficacy of methenamine salts in patients with chronic indwelling bladder catheters recently has been questioned.26
Trimethoprim-sulfamethoxazole (TM P-SM X ).
TMP-SMX is a fixed combination of drugs which
acts additively or synergistically against a wide range
of gram-positive (including enterococci) and gramnegative organisms, except Pseudomonas and Alcali-
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genes sp . The list of indications for TMP-SMX continues to grow and presently includes infections due
to Shigella sp, Salmonella typhi, ampicillin-resistant
Haemophilus infiuenzae, and Pneumocystis carinii,
and diseases such as acute exacerbations of chronic
bronchitis, acute otitis media, and gonococcal urethritis.27 Its most practical applications are the treatment of and prophylaxis for recurrent UTis caused
by susceptible organisms. 25 Emergence of resistant
organisms in the fecal flora has not been a major
problem and because trimethoprim penetrates prostatic tissue, TMP-SMX is probably the drug of choice
for recurrent or chronic prostatic infection. 28 The
adverse effects of TMP-SMX represent the sum of
reactions to trimethoprim (folate deficiency syndromes and possible teratogenic effects) and sulfamethoxazole (see above) . The drug may be used in mildto-moderate renal failure. 29

Urinary Tract Infections

Urinary tract infections represent a broad group
of clinical entities with bacteriuria as the common
thread . Many classifications are possible, but those
which include not only the type of infection but also
the site of involvement allow for the most accurate
assessment of antibiotic therapy . Although the site of
infection in many instances is unknown, enough evidence is available to analyze antibiotic therapy in the
following clinical categories of UTI: acute uncomplicated UTI; recurrent UTI ; complicated UTI; asymptomatic bacteriuria; and catheter-related UTI.
A cute uncomplicated UT/s usually represent the
first or second infection in young sexually active
women without underlying urinary tract abnormalities, and are caused by antibiotic enteric bacilli (most
commonly E coli) which emanate from antibiotic
fecal flora . This type of infection responds well to
practically all commonly used oral antibiotics, but
because they are effective, inexpensive, and well-tolerated, the oral, nonabsorbable sulfonamides remain
the therapy of choice. Treatment is usually given for 7
to 14 days . Longer courses of therapy are usually not
necessary. Many alternative agents exist (see Table),
but none have proven superior to the sulfonamides
and most are more expensive. In the absence of an
obstructive or neurogenic lesion , the urine should be
sterile between 48 to 72 hours (Figure). If bacteriuria
persists, therapy should be guided by the results of
sensitivity testing.
Some patients with acute symptomatic infection
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fail to respond to the initial antibiotic therapy or
suffer recurrence of the infection. The recurrence may
be a relapse of the initial infection with the same
pathogen, suggesting a parenchymal focus of infection in the kidney or prostate or may be caused by
different organisms, so-called reinfections. The source
for reinfection is almost always the bowel flora. Approximately 80% of recurrences are reinfections and
most are limited to the bladder. Antibiotic sensitivity
testing assumes added importance in this situation
because the pathogen will probably not be sensitive
to sulfonamides if used initially. Ampicillin, tetracyclines, cephalosporins, and TMP-SMX are preferred
and are given orally for IO to 14 days. Each course of
therapy will result in a 20% to 25% long-term cure
rate. 11 Those having a second or third episode of
infection should probably be evaluated urologically
or radiographically (see Figure). Those with occasional recurrences ( three or less per year) can be
treated like acute uncomplicated infection. With
more frequent recurrences, especially in the absence
of urological abnormalities, the precise duration of
therapy is not well established . Closely spaced recurrences are likely to be due to relapse and some have
suggested treating true relapses for six weeks to one
year. 10 Most authorities suggest six weeks of therapy
with the realization that the optimal duration of therapy for this group of patients is controversial. An
alternative approach consists of intensive initia l treatment for 10 to 14 days, followed by daily low-dose
nitrofurantoin (100 mg) or TMP-SMX (one half to
one tablet). Prophylaxis should be continued for up
to six months, then discontinued, and the patient
observed.
A cute complicated UTls are a third category of
infections; they are almost always associated with
underlying genitourinary tract or neurological disorders. Isolated organisms tend to be multiply
drug-resistant. Permanent eradication of the bacteriuria is unlikely, but the goal is to control symptoms. Initial therapy ideally should be based on
sensitivity studies, but pending culture results, an
aminoglycoside antibiotic, that is, gentamicin, is an
obvious choice. Therapy for IO to 14 days is usually
adequate. Emergence of resistant organisms in this
setting is a probable event.
Asymptomatic bacteriuria represents a large
group of UTis with an incidence ranging from 1.2%
in pre-school girls to over 15% in women over age
60. 11 Certain groups are known to be at risk for
acquiring significant asymptomatic bacteriuria and

subsequent symptomatic UTI. Included are pregnant
women in the first trimester, women with diabetes,
preschool- and school-age girls, and those with a
previous history of urinary tract instrumentation .
About 5% of pregnant women will have asymptomatic bacteriuria at the first prenatal visit and 20% to
40% of these will develop acute pyelonephritis. 9 Assuming that acute renal infection in the mother contributes to prematurity and fetal mortality, treatment
should be initiated. The preferred agents are the penicillins, cephalosporins, nitrofurantoin, and shortacting sulfonamides (first trimester only). Treatment
will eliminate bacteriuria in 80% of these patients.
Some will have recurrence and for these patients,
nightly prophylaxis through term with nitrofurantoin
is recommended. The necessity to treat other groups
of patients with asymptomatic bacteriuria is less certain, especially elderly women in whom bacteriuria
tends to be recurrent even in the a bsence of underlying disease. Available evidence indicates that, in
adults, progressive renal damage due to UTI is an
uncommon occurrence in the absence of obstruction .10 Several attempts at eradication seem worthwhile. If bacteriuria recurs, genitourinary evaluation
is warranted. If no abnormalities are found, no further therapy is necessary in the elderly.
Catheter-related infections are the most common
hospital-acquired infections and the most frequent
causes of gram-negative bacteremia.•·11 Patients acquiring bacteriuria with short-term closed drainage
should be treated with an effective antibiotic for 7 to
10 days after the catheter is removed . Long-term
drainage represents a different problem. Patients on
long-term drainage are continuously infected but
usually do well. Antibiotics will not clear bacteriuria
permanently while the catheter remains in place.
Therapy is reserved for acute episodes of infection .
A scheme for the management of patients with
bacteriuria is given in the accompanying Figure. It is
meant to serve only as a guide for the practicing
physician and should be modified in light of future
improvements in the diagnosis, localization, and
therapy of UTis. Optimal therapy awaits a more
precise classification of UTis, the end result of which
will be a reduction in morbidity and mortality from
UTis, and a significant decrease in the cost of related
health care.

The figure is reproduced with permission from Urinary Tract
Infection and Its Management, Donald Kaye (ed).
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